162 related articles for article (PubMed ID: 33614733)
1. Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Li ZY; Chen M; Zhao MH
Kidney Dis (Basel); 2021 Jan; 7(1):50-56. PubMed ID: 33614733
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Kronbichler A; Kerschbaum J; Gopaluni S; Tieu J; Alberici F; Jones RB; Smith RM; Jayne DRW
Ann Rheum Dis; 2018 Oct; 77(10):1440-1447. PubMed ID: 29950327
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
4. Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy.
Yoneva T; Zdravkova Y; Kotov G; Ivanova Todorova E; Vasilev G; Rashkov R; Sheytanov I
Arch Rheumatol; 2023 Sep; 38(3):397-405. PubMed ID: 38046244
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
[TBL] [Abstract][Full Text] [Related]
6. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 33309337
[TBL] [Abstract][Full Text] [Related]
7. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
9. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
Harris C; Marin J; Beaulieu MC
BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
[TBL] [Abstract][Full Text] [Related]
10. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cortazar FB; Pendergraft WF; Wenger J; Owens CT; Laliberte K; Niles JL
Arthritis Rheumatol; 2017 May; 69(5):1045-1053. PubMed ID: 28029751
[TBL] [Abstract][Full Text] [Related]
11. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.
Thery-Casari C; Euvrard R; Mainbourg S; Durupt S; Reynaud Q; Durieu I; Belot A; Lobbes H; Cabrera N; Lega JC
Autoimmun Rev; 2020 May; 19(5):102505. PubMed ID: 32173512
[TBL] [Abstract][Full Text] [Related]
12. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
Segelmark L; Flores-Suárez L; Mohammad A
Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
[TBL] [Abstract][Full Text] [Related]
13. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Jones RB; Ferraro AJ; Chaudhry AN; Brogan P; Salama AD; Smith KG; Savage CO; Jayne DR
Arthritis Rheum; 2009 Jul; 60(7):2156-68. PubMed ID: 19565480
[TBL] [Abstract][Full Text] [Related]
14. Implication of Serious Infections in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the First Cycle of Rituximab: A Pilot Study in a Single Korean Center.
Do H; Pyo JY; Sup ; Sup ; Song JJ; Sup ; Sup ; Park YB; Sup ; Sup ; Lee SW; Sup ; Sup
J Rheum Dis; 2023 Jan; 30(1):45-52. PubMed ID: 37476530
[TBL] [Abstract][Full Text] [Related]
15. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
JAMA; 2021 Jun; 325(21):2178-2187. PubMed ID: 34061144
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
17. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Mohammad AJ; Segelmark M; Smith R; Englund M; Nilsson JÅ; Westman K; Merkel PA; Jayne DRW
J Rheumatol; 2017 Oct; 44(10):1468-1475. PubMed ID: 28765251
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
[TBL] [Abstract][Full Text] [Related]
19. Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.
Chu X; Hong Y; Wang Y; Yu C; Wang L; Tong H; Yan J; Zhang Z; Xu G; Yao Y; Zeng R
Am J Nephrol; 2021; 52(12):899-908. PubMed ID: 34875652
[TBL] [Abstract][Full Text] [Related]
20. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
